SCHEMBL2170400

SCHEMBL2170400

CCOC(=O)CON=Cc1cc(Br)c(Oc2ccc(O)c(C(=O)c3ccc(Cl)cc3)c2)c(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.39
THRB P10828 4/20 0.38
THRA P10827 3/20 0.38
PTPN1 P18031 1/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
NCOA1 Q15788 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495867 1.00 HPGD (0.39) HPGDTHRBTHRAPTPN1KMT2A
SCHEMBL2170053 0.93 HPGD (0.40) HPGDTHRBTHRAPTPN1MAPT
SCHEMBL2170048 0.93 HPGD (0.40) HPGDTHRBTHRAPTPN1MAPT
SCHEMBL2169308 0.91 HPGD (0.39) HPGDTHRBTHRAPTPN1KMT2A
SCHEMBL2170441 0.91 HPGD (0.39) HPGDTHRBTHRAPTPN1KMT2A
SCHEMBL2170562 0.89 THRB (0.43) THRBTHRA
SCHEMBL2170568 0.89 THRB (0.43) THRBTHRA
SCHEMBL16496563 0.87 THRB (0.38) THRBTHRAKMT2AMEN1MAPT
SCHEMBL2169679 0.87 THRB (0.38) THRBTHRAKMT2AMEN1MAPT
SCHEMBL16496223 0.83 THRB (0.41) THRBTHRAKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA HPGD 3201/4885THRB 2/4885THRA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.